

NeuroSearch A/S
Pederstrupvej 93
DK - 2750 Ballerup
Denmark
Telephone: +45 4460 8000
Telefax: +45 4460 8080
ns@neurosearch.dk
www.neurosearch.com
CVR No: DK-12 54 61 06

Announcement

NeuroSearch A/S' share capital and voting rights

On 3 March 2009, NeuroSearch increased its share capital with the issue of 530,745 new shares of DKK 20 nominal value each at a price of DKK 187 per share. The shares were issued to Eli Lilly and Company as part of a payment to NeuroSearch relating to the signing of a new three-year drug discovery and development alliance in February 2009.

Pursuant to section 6 of Executive Order no. 1273 of 16 December 2008 on Issuers' Disclosure Obligations, it is hereby announced that at the end of March 2009, the total nominal value of NeuroSearch A/S' share capital is DKK 325,480,600, which is made up of 16,274,030 shares with a nominal value of DKK 20 each, and corresponding to 325,480,600 votes.

Flemming Pedersen
CEO

Contact person:

Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate Communications, telephone: +45 4017 5103

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on Nasdaq OMX Copenhagen. The company's core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and CNS disorders. A substantial share of NeuroSearch's activities is partner financed through an alliance with Eli Lilly and Company and collaborations with GlaxoSmithKline and Abbott. The drug pipeline comprises seven clinical (Phase I-III) development programmes: ACR16 for Huntington's disease (Phase III), tesofensine for obesity (Phase III ready), ABT-894 for ADHD (Phase II) in partnership with Abbott, ACR325 for Parkinson's disease (Phase II ready), ACR343 for schizophrenia (Phase II ready), ABT-560 for the treatment of various CNS disorders (Phase I) in collaboration with Abbott and NSD-788 for anxiety/depression (Phase I). In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.

